https://www.socictopen.socict.org/files/original/c993795e7b4d06c8a90bd8209e6f9270.pdf 05afbcb249dd67b79fea40754b63428d Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional Analysis Creator An entity primarily responsible for making the resource Xiantao Zeng, Ying-Hui Jin, Jianguang Ji, Di Huang, Lin-Lu Ma, Yun-Yun Wang, Bing-Hui Li, Xuan Yin, Bing-Hui Li, Jia-Yu Yang, Jia-Yu Yang, Tong Deng, Xue-Qun Ren Description An account of the resource ObjectiveThe quality and rationality of many recently registered clinical studies related to coronavirus disease 2019 (COVID-19) needs to be assessed. Hence, this study aims to evaluate the current status of COVID-19 related registered clinical trial.MethodsWe did an electronic search of COVID-19 related clinical studies registered between December 1, 2019 and February 21, 2020 (updated to May 28, 2020) from the ClinicalTrials.gov, and collected registration information, study details, recruitment status, characteristics of the subjects, and relevant information about the trial implementation process.ResultsA total of 1,706 studies were included 10.0% of which (n=171) were from France, 943 (55.3%) used an interventional design, and 600 (35.2%) used an observational design. Most of studies (73.6%) aimed to recruit fewer than 500 people. Interferon was the main prevention program, and antiviral drugs were the main treatment program. Hydroxychloroquine and chloroquine (230/943, 24.4%) were widely studied. Some registered clinical trials are incomplete in content, and 37.4% of the 1,706 studies may have had insufficient sample size.ConclusionThe quality of COVID-19 related studies needs to be improved by strengthening the registration process and improving the quality of clinical study protocols so that these clinical studies can provide high-quality clinical evidence related to COVID-19. Date A point or period of time associated with an event in the lifecycle of the resource 2020 Subject The topic of the resource Clinical trial, SARS-CoV-2, Coronavirus disease 2019, ClinicalTrials.gov, registration Identifier An unambiguous reference to the resource within a given context 10.3389/fphar.2020.540187 Source A related resource from which the described resource is derived Epidemiology and Health Publisher An entity responsible for making the resource available Korean Society of Epidemiology Coverage The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant Therapeutics. Pharmacology